Scarica l'app Stockscreener
23.21
1.57%
-0.37
Dopo l'orario di chiusura:
23.03
-0.18
-0.78%
Precedente Chiudi:
$23.58
Aprire:
$23.58
Volume 24 ore:
761.62K
Relative Volume:
0.41
Capitalizzazione di mercato:
$2.41B
Reddito:
$71.78M
Utile/perdita netta:
$-295.28M
Rapporto P/E:
-7.3456
EPS:
-3.1597
Flusso di cassa netto:
$-271.85M
1 W Prestazione:
-0.73%
1M Prestazione:
-4.33%
6M Prestazione:
+40.50%
1 anno Prestazione:
+106.13%
Intervallo 1D:
$23.07
$23.78
Intervallo di 1 settimana:
$22.55
$24.64
Portata 52W:
$8.195
$24.95
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
23.21 | 2.43B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics Inc (NRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nurix Therapeutics Inc (NRIX) Institutional Confidence - TradingKey
Nurix Therapeutics Inc (NRIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nurix Therapeutics Inc (NRIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nurix Therapeutics Inc (NRIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRIX|Nurix Therapeutics Inc|Price:23.380|Chg%:-0.360 - TradingKey
TradingKey - TradingKey
Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nurix Therapeutics Inc (NRIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRIX: Nurix Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
NRIX Maintained by UBS -- Price Target Raised to $31 - GuruFocus
UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating - Moomoo
UBS Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Why Did Nurix Therapeutics (NASDAQ:NRIX) Announce Key Clearance? - Kalkine Media
Nurix closes $700m Roche collaboration for bexobrutideg By Investing.com - Investing.com Nigeria
Nurix closes $700m Roche collaboration for bexobrutideg - Investing.com
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - The Manila Times
Nurix to Receive $700M Upfront in Roche Bexobrutideg Deal - Stock Titan
Nurix Therapeutics, Inc. (NRIX) stock price, news, quote and history - Yahoo Finance UK
Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones - Stock Traders Daily
How Investors May Respond To Nurix Therapeutics (NRIX) Deepening Losses And Sharply Lower Collaboration Revenue - webull.com
Oppenheimer Maintains Nurix Therapeutics (NRIX) Outperform Recommendation - MSN
Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study - Traders Union
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% Upside - TradingView
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimates for Nurix Therapeutics Cut by HC Wainwright - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating - Moomoo
NRIX Maintained by Mizuho -- Price Target Raised to $34.00 - GuruFocus
Mizuho Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Mizuho Securities Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nurix stock price target raised to $34 by Mizuho on Roche deal - Investing.com UK
55,138 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Raised to Sell at Wall Street Zen - MarketBeat
Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates - MSN
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $28 to $40 - Moomoo
MSN Money - MSN
NURIX THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $34 FROM $32 - webull.com
Analysts Offer Insights on Healthcare Companies: TruBridge (TBRG), AbbVie (ABBV) and Nurix Therapeutics (NRIX) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ) - The Globe and Mail
NRIX Maintained by HC Wainwright & Co. -- Price Target Raised to $34 - GuruFocus
Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside - TradingView
NRIX Maintained by Truist Securities -- Price Target Raised to $34.00 - GuruFocus
RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33 - Moomoo
Nurix stock price target raised to $34 by H.C. Wainwright By Investing.com - Investing.com India
Mizuho raises Nurix stock price target to $34 on Roche deal By Investing.com - Investing.com South Africa
Mizuho raises Nurix stock price target to $34 on Roche deal - Investing.com
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nurix Therapeutics Inc Azioni (NRIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
Jul 30 '26 |
Sale |
23.38 |
2,845 |
66,524 |
44,927 |
| Ring Christine | Chief Legal Officer |
Jul 30 '26 |
Option Exercise |
0.00 |
10,180 |
0 |
23,759 |
| Ring Christine | Chief Legal Officer |
Jul 30 '26 |
Sale |
23.38 |
3,847 |
89,954 |
19,912 |
| Hansen Gwenn | Chief Scientific Officer |
Jul 30 '26 |
Option Exercise |
0.00 |
10,180 |
0 |
125,185 |
| Hansen Gwenn | Chief Scientific Officer |
Jul 30 '26 |
Sale |
23.38 |
3,847 |
89,954 |
121,338 |
| Ring Christine | Chief Legal Officer |
Jul 02 '26 |
Option Exercise |
5.47 |
11,008 |
60,174 |
24,587 |
| Ring Christine | Chief Legal Officer |
Jul 02 '26 |
Sale |
23.56 |
11,008 |
259,366 |
13,579 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):